Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion

Cardiovascular Drugs and Therapy

Volumn 25, Issue 3, 2011, Pages 223-232

  Huang, Ming He ^a,b   Wu, Yewen ^a   Nguyen, Vincent ^a   Rastogi, Saurabh ^a   McConnell, Bradley K ^c   Wijaya, Cori ^c   Uretsky, Barry F ^a   Poh, Kian Keong ^d   Tan, Huay Cheem ^d   Fujise, Kenichi ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b Gulf Coast Heart Clinic League City   (United States)

^c UNIVERSITY OF HOUSTON   (United States)

^d NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Akt; Esmolol; Milrinone; PKA; Reperfusion injury

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; ESMOLOL; MILRINONE; PROTEIN KINASE B; PROTEIN KINASE B BETA; PROTEIN KINASE INHIBITOR; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART VENTRICLE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; RAT;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ANIMALS; APOPTOSIS; CARDIOTONIC AGENTS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DISEASE MODELS, ANIMAL; IN SITU NICK-END LABELING; INFUSIONS, INTRAVENOUS; MILRINONE; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; MYOCYTES, CARDIAC; PHOSPHODIESTERASE 3 INHIBITORS; PROPANOLAMINES; RATS;

EID: 79958282048     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-011-6302-z     Document Type: Article

References (28)

1. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischemia-reperfusion injury: targeting the reperfusion injury salvage kinase (RISK)-pathway (review). Cardiovasc Res. 2004;61:448-60. (Pubitemid 38210151)
2. Ovitz M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy D, et al. Postconditioning and protection from reperfusion injury: where do we stand? Cardiovasc Res (Review). 2010;87:406-23.
3. Skyschally A, Gaster PV, Boengler K, Gres P, Musiolik J, Schilawa D, et al. Ischemic postconditioning in pigs no causal role for RISK activation. Circ Res. 2009;104:15-8.
4. Huang MH, Friend DS, Sunday ME, Singh K, Haley K, Austen KF, et al. An intrinsic adrenergic system in mammalian heart. J Clin Invest. 1996;98:1298-303. (Pubitemid 26322054)
5. 2-adrenergic receptor: role of the intrinsic cardiac adrenergic cell. Am J Physiol Heart Circ Physiol. 2007;293:H376-84.
6. Huang MH, Nguyen V, Wu Y, Rastogi S, Birnbaum Y, Lui CY, et al. Reducing ischemia/reperfusion injury through δ-opioidregulated intrinsic cardiac adrenergic cells: adrenopeptidergic co-signaling. Cardiovasc Res. 2009;84:452-60.
7. Aiyar N, Rand K, Elshourbagy NA, Zeng Z, Adamou JE, Bergsma DJ, et al. A cDNA encoding the calcitonin gene-related peptide type 1 receptor. J Biol Chem. 1996;271:11325-9. (Pubitemid 26155969)
8. 2+-mobilization involved in CGRP-mediated positive inotropic effect in ventricular myocytes. Am J Physiol Regul Integr Comp Physiol. 1999;276:R259-64.
9. Tong H, Bernstein ME, Steenbergen C. The role of beta-adrenergic receptor signaling in cardioprotection. FASEB J. 2005;19:983-5. (Pubitemid 40827725)
10. 2-adrenergic receptor agonist confers synergistic infarct size reduction. Circ Res (abstract). 2007;101:1210.
11. 2-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation. 1999;100:2210-2.
12. 2-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci USA. 2001;98:1607-12.
13. Haikala H, Kaheinen P, Levijoki, Linden IB. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of new calcium sensitizer Levosimendan. Cardiovasc Res. 1997;34:536-46. (Pubitemid 27272673)
14. Sanada S, Kitakaze M, Papst PJ, Asanuma H, Node K, Takashima S, et al. Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitor: the role of protein kinases A and p38 mitogen-activated protein kinase. Circulation. 2001;104:705-10. (Pubitemid 32738527)
15. Geissler HJ. Reduction of myocardial reperfusion injury by highdose beta-blocker with esmolol. Thorac Cardiovasc Surg. 2002;50:367-72. (Pubitemid 35477424)
16. Killingsworth CR, Wei C-C, Dell'Italia LJ, Ardell JL, Kingsley MA, Smith WM, et al. Short-acting β-adrenergic antagonist esmolol given at reperfusion improves survival after prolonged ventricular fibrillation. Circulation. 2004;109:2469-74. (Pubitemid 38679569)
17. Hein M, Roehl AB, Baumert JH, Scherer K, Steendijk P, Rossaint R. Anti-ischemic effects of inotropic agents in experimental right ventricular infarction. Acta Anaesthesiol Scand. 2009;53:941-8.
18. Wu Y, Yin X, Wijaya C, Huang M, McConnell BK. Acute myocardial infarction in rats. JoVE. 2011, 48: http://www.jove.com/index/details.stp?ID=2464. doi: 10.3791/2464.
19. Katzberg AA, Farmer BB, Harris RA. The predominance of binucleation in isolated rat heart myocytes. Am J Anat. 2005;149:489-99.
20. Campbell CA, Reddy BR, Alker KJ, Wynne J, Kloner RA. Effect of milrinone on acute myocardial infarct size. Am J Cardiol. 1987;60:422-3.
21. Fukasawa M, Nishida H, Sato T, Miyazaki M, Nakaya H. 6-[4-(1-Cyclohexyl- 1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2-(1H)quinolinone (cilostazol), a phosphodiesterase type 3 inhibitor, reduces infarct size via activation of mitochondrial Ca2+-activated K+ channels in rabbit hearts. J Pharmacol Exp Ther. 2008;326:100-4. (Pubitemid 351872116)
22. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008;359:473-81.
23. Morisco C, Condorelli G, Trimarco V, Bellis A, Marrone C, Sadoshima J, et al. Akt mediates the cross-talk between betaadrenergic and insulin receptors in neonatal cardiomyocytes. Circ Res. 2005;96:180-8. (Pubitemid 40209365)
24. Halkin A, Grines CL, Cox DA, Garcia E, Mehran R, Tcheng JE, et al. Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. J Am Coll Cardiol. 2004;43:1780-7. (Pubitemid 38622514)
25. Pedersen TR. The Norwegian multicenter study of timolol after myocardial infarction. Circulation. 1983;67:I49-53.
26. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339:489-97. (Pubitemid 28384881)
27. Karlsberg RP, DeWood MA, DeMaria AN, Berk MR, Lasher KP. Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. Milrinone-Dobutamine Study Group. Clin Cardiol. 1996;19:21-30.
28. Mooss AN, Hilleman DE, Mohiuddin SM, Hunter CB. Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy. Ann Pharmacother. 1994;28:701-3. (Pubitemid 24200918)